REVIVA PHARMACEUTICALS HOLDI (RVPH) Forecast, Price Target & Analyst Ratings

NASDAQ:RVPHUS76152G2093

Current stock price

0.9004 USD
+0.01 (+1.25%)
At close:
0.885 USD
-0.02 (-1.71%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REVIVA PHARMACEUTICALS HOLDI (RVPH).

Forecast Snapshot

Consensus Price Target

Price Target
$77.52
+ 8,509.51% Upside

Next Earnings Forecast

Earnings Estimate
Release Date
May 18, 2026
Period
Q1 / 2026
EPS Estimate
-$1.04
Revenue Estimate

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$77.52
Upside
+ 8,509.51%
From current price of $0.90 to mean target of $77.52, Based on 12 analyst forecasts
Low
$30.30
Median
$40.80
High
$210.00

Price Target Revisions

1 Month
1,318.68%
3 Months
1,266.29%

Price Target Summary

12 Wall Street analysts provided a forecast for the next 12 months for RVPH. The average price target is 77.52 USD. This implies a price increase of 8509.51% is expected in the next year compared to the current price of 0.9004.
The average price target has been revised upward by 1266.29% in the past 3 months.

Analyst Ratings & History

Current Analyst Ratings

RVPH Current Analyst RatingRVPH Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

RVPH Historical Analyst RatingsRVPH Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
RVPH was analyzed by 12 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about RVPH.
In the previous month the buy percentage consensus was at a similar level.
RVPH was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-08Maxim GroupDowngrade Buy -> Hold
2026-03-05D. Boral CapitalDowngrade Buy -> Hold
2026-01-05Chardan CapitalMaintains Buy -> Buy
2025-12-23D. Boral CapitalMaintains Buy -> Buy
2025-12-23HC Wainwright & Co.Reiterate Buy -> Buy
2025-11-19D. Boral CapitalMaintains Buy -> Buy
2025-10-28D. Boral CapitalMaintains Buy -> Buy
2025-10-27HC Wainwright & Co.Maintains Buy -> Buy
2025-09-29Chardan CapitalInitiate Buy
2025-09-19D. Boral CapitalMaintains Buy -> Buy
2025-09-15BenchmarkMaintains Speculative Buy -> Speculative Buy
2025-08-18D. Boral CapitalMaintains Buy -> Buy
2025-08-18Roth CapitalReiterate Buy -> Buy
2025-08-15Maxim GroupMaintains Buy -> Buy
2025-06-27D. Boral CapitalMaintains Buy -> Buy
2025-06-03D. Boral CapitalMaintains Buy -> Buy
2025-05-20D. Boral CapitalMaintains Buy -> Buy
2025-04-24D. Boral CapitalMaintains Buy -> Buy
2025-04-01D. Boral CapitalMaintains Buy -> Buy
2025-01-22HC Wainwright & Co.Maintains Buy -> Buy
2025-01-21D. Boral CapitalMaintains Buy -> Buy
2025-01-10Roth MKMInitiate Buy
2025-01-10Maxim GroupUpgrade Hold -> Buy
2024-11-14D. Boral CapitalMaintains Buy -> Buy
2024-11-13D. Boral CapitalMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 18, 2026
Period
Q1 / 2026
EPS Estimate
-$1.04
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
59.91%
Number of Analysts
8

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
2.67%
EPS (3 Months)
-1,068.00%

Next Earnings Summary

RVPH is expected to report earnings on 5/18/2026. The consensus EPS estimate for the next earnings is -1.04 USD and the consensus revenue estimate is 0 USD.

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
RVPH revenue by date.RVPH revenue by date.
N/AN/AN/AN/A
-100.00%
N/AN/A
107.28%
N/A
42.26%
N/A
32.10%
EBITDA
YoY % growth
RVPH ebitda by date.RVPH ebitda by date.
N/A-724.1K-10.105M
-1,295.46%
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
RVPH ebit by date.RVPH ebit by date.
-152.8K-724.7K
-374.28%
-10.105M
-1,294.30%
-28.229M
-179.37%
-39.504M
-39.94%
-30.799M
22.04%
-20.2M
34.41%
N/A
-53.04%
N/A
-54.97%
N/A
59.25%
N/A
-343.23%
N/A
122.92%
N/A
622.14%
N/A
73.80%
N/A
47.47%
Operating Margin
RVPH operating margin by date.RVPH operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
RVPH eps by date.RVPH eps by date.
N/AN/A-0.56
83.85%
-25.00
-4,364.29%
-32.80
-31.20%
-18.20
44.51%
N/A
60.99%
N/A
56.23%
N/A
9.00%
N/A
-14.10%
N/A
86.72%
N/A
138.10%
N/A
306.25%
N/A
64.62%
N/A
40.19%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth
-1.04
59.91%
-1.08
55.20%
-0.65
45.77%
-0.74
38.11%
-0.21
79.45%
-0.21
80.08%
-0.23
63.95%
-0.24
66.76%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-6.112M
6.52%
-7.375M
-21.43%
-8.638M
-114.35%
-9.641M
-170.88%
-14.217M
-132.61%
-14.835M
-101.16%
-16.071M
-86.06%
-16.689M
-73.11%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2030 2031 2032 2033 200M 400M 600M
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
22.64%
EPS Next 5 Year
14.60%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

REVIVA PHARMACEUTICALS HOLDI / RVPH Forecast FAQ

Can you provide the average price target for REVIVA PHARMACEUTICALS HOLDI stock?

12 analysts have analysed RVPH and the average price target is 77.52 USD. This implies a price increase of 8509.51% is expected in the next year compared to the current price of 0.9004.

What is the next earnings date for RVPH stock?

REVIVA PHARMACEUTICALS HOLDI (RVPH) will report earnings on 2026-05-18.

Can you provide the consensus estimates for REVIVA PHARMACEUTICALS HOLDI next earnings?

The consensus EPS estimate for the next earnings of REVIVA PHARMACEUTICALS HOLDI (RVPH) is -1.04 USD and the consensus revenue estimate is 0 USD.

Can you provide the consensus rating for REVIVA PHARMACEUTICALS HOLDI stock?

The consensus rating for REVIVA PHARMACEUTICALS HOLDI (RVPH) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.